Molecular Partners AG (MOLN)
NASDAQ: MOLN · IEX Real-Time Price · USD
3.745
+0.025 (0.67%)
At close: May 17, 2024, 3:58 PM
3.620
-0.125 (-3.34%)
After-hours: May 17, 2024, 4:00 PM EDT
Molecular Partners AG Market Cap
Molecular Partners AG has a market cap or net worth of $125.43 million as of May 17, 2024. Its market cap has decreased by -42.60% in one year.
Market Cap
125.43M
Enterprise Value
-62.46M
1-Year Change
-42.60%
Ranking
Category
Stock Price
$3.75
Market Cap Chart
Since the IPO on June 16, 2021, Molecular Partners AG's market cap has decreased from $683.35M to $125.43M, a decrease of -81.65%. That is a compound annual growth rate of -44.04%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
May 17, 2024 | 124.20M | -2.36% |
May 16, 2024 | 127.20M | 4.35% |
May 15, 2024 | 121.90M | 4.55% |
May 14, 2024 | 116.60M | -6.57% |
May 13, 2024 | 124.80M | - |
May 10, 2024 | 124.80M | 2.63% |
May 9, 2024 | 121.60M | -1.54% |
May 8, 2024 | 123.50M | 3.00% |
May 7, 2024 | 119.90M | 1.10% |
May 6, 2024 | 118.60M | -9.33% |
May 3, 2024 | 130.80M | 5.74% |
May 2, 2024 | 123.70M | -2.68% |
May 1, 2024 | 127.10M | 2.33% |
Apr 30, 2024 | 124.20M | 2.14% |
Apr 29, 2024 | 121.60M | -4.63% |
Apr 26, 2024 | 127.50M | - |
Apr 25, 2024 | 127.50M | - |
Apr 24, 2024 | 127.50M | - |
Apr 23, 2024 | 127.50M | - |
Apr 22, 2024 | 127.50M | 16.87% |
Apr 19, 2024 | 109.10M | -11.23% |
Apr 18, 2024 | 122.90M | -4.36% |
Apr 17, 2024 | 128.50M | - |
Apr 16, 2024 | 128.50M | -1.00% |
Apr 15, 2024 | 129.80M | - |
View and export this data all the way back to 2021.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
PDS Biotechnology | 126.18M |
Omega Therapeutics | 125.75M |
Sangamo Therapeutics | 125.31M |
Amylyx Pharmaceuticals | 123.77M |
VistaGen Therapeutics | 123.51M |
Nuvectis Pharma | 122.07M |
Cellectar Biosciences | 120.81M |
Adicet Bio | 120.62M |